Genetics of Obsessive-Compulsive Disorder logy 2005;52:176-82. 43. Nakamura M, Ueno S, Sano A, Tanabe H. The human serotonin transporter gene linked polymorphism (5- HTTLPR) shows ten novel allelic variants. Mol Psy- chiatry 2000;5:32-8. 44. Hu XZ, Lipsky RH, Zhu G, Akhtar LA, Taubman J, Greenberg BD, et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive- compulsive disorder. Am J Hum Genet 2006;78:815-26. 45. Greenberg BD, Benjamin J, Martin JD, Keuler D, Huang SJ, Altemus M, et al. Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients. Psychopharmacology (Berl) 1998; 140:434-44. 46. Hollander E, DeCaria CM, Nitescu A, Gully R, Suckow RF, Cooper TB, et al. Serotonergic function in obses- sive-compulsive disorder. Behavioral and neuroendo- crine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry 1992;49:21-8. 47. Enoch MA, Greenberg BD, Murphy DL, Goldman D. Sexually dimorphic relationship of a 5-HT2A promoter polymorphism with obsessive-compulsive disorder. Biol Psychiatry 2001;49:385-8. 48. Walitza S, Wewetzer C, Warnke A, Gerlach M, Geller F, Gerber G, et al. 5-HT2A promoter polymorphism -1438G/A in children and adolescents with obsessive- compulsive disorders. Mol Psychiatry 2002;7:1054-7. 49. Meira-Lima I, Shavitt RG, Miguita K, Ikenaga E, Miguel EC, Vallada H. Association analysis of the catechol-o- methyltransferase (COMT), serotonin transporter (5- HTT) and serotonin 2A receptor (5HT2A) gene poly- morphisms with obsessive-compulsive disorder. Genes Brain Behav 2004;3:75-9. 50. Tot S, Erdal ME, Yazici K, Yazici AE, Metin O. T102C and -1438 G/A polymorphisms of the 5-HT2A receptor gene in Turkish patients with obsessive-compulsive disorder. Eur Psychiatry 2003;18:249-54. 51. Nicolini H, Cruz C, Camarena B, Orozco B, Kennedy JL, King N, et al. DRD2, DRD3 and 5HT2A receptor genes polymorphisms in obsessive-compulsive dis- order. Mol Psychiatry 1996;1:461-5. 52. Graf M. 5-HT2c receptor activation induces grooming behaviour in rats: possible correlations with obsessive- compulsive disorder. Neuropsychopharmacol Hung 2006;8:23-8. 53. Cavallini MC, Di Bella D, Pasquale L, Henin M, Bellodi L. 5HT2C CYS23/SER23 polymorphism is not asso- ciated with obsessive-compulsive disorder. Psychiatry Res 1998;77:97-104. 54. Gross-Isseroff R, Cohen R, Sasson Y, Voet H, Zohar J. Serotonergic dissection of obsessive compulsive symp- toms: a challenge study with m-chlorophenylpiperazine and sumatriptan. Neuropsychobiology 2004;50:200-5. 55. Stern L, Zohar J, Cohen R, Sasson Y. Treatment of severe, drug resistant obsessive compulsive disorder with the 5HT1D agonist sumatriptan. Eur Neuropsy- chopharmacol 1998;8:325-8. 56. Mundo E, Richter MA, Sam F, Macciardi F, Kennedy JL. Is the 5-HT(1Dbeta) receptor gene implicated in the pathogenesis of obsessive-compulsive disorder? Am J Psychiatry 2000;157:1160-1. 57. Mundo E, Richter MA, Zai G, Sam F, McBride J, Macciardi F, et al. 5HT1Dbeta receptor gene implicated in the pathogenesis of obsessive-compulsive disorder: further evidence from a family-based association study. Mol Psychiatry 2002;7:805-9. 58. Camarena B, Aguilar A, Loyzaga C, Nicolini H. A family-based association study of the 5-HT-1Dbeta receptor gene in obsessive-compulsive disorder. Int J Neuropsychopharmacol 2004;7:49-53. 59. Di Bella D, Cavallini MC, Bellodi L. No association between obsessive-compulsive disorder and the 5-HT (1Dbeta) receptor gene. Am J Psychiatry 2002;159:1783- 5. 60. Lochner C, Hemmings SM, Kinnear CJ, Moolman- Smook JC, Corfield VA, Knowles JA, et al. Cor- rigendum to "gender in obsessive-compulsive disorder: clinical and genetic findings" [Eur. Neuropsychophar- macol. 14 (2004) 105-113]. Eur Neuropsychopharmacol 2004;14:437-45. 61. Nielsen DA, Dean M, Goldman D. Genetic mapping of the human tryptophan hydroxylase gene on chromo- some 11, using an intronic conformational polymor- phism. Am J Hum Genet 1992;51:1366-71. 62. Walther DJ, Peter JU, Bashammakh S, Hortnagl H, Voits M, Fink H, et al. Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 2003; 299:76. 63. Mossner R, Walitza S, Geller F, Scherag A, Gutknecht L, Jacob C, et al. Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in children and adolescents with obsessive-com- pulsive disorder. Int J Neuropsychopharmacol 2006;9: 437-42. 64. Stein DJ. The neurobiology of obsessive-compulsive disorder. Neuroscientist 1996;2:300-5. 65. Goodman WK, McDougle CJ, Price LH, Riddle MA, Pauls DL, Leckman JF. Beyond the serotonin hypo- thesis: a role for dopamine in some forms of obsessive compulsive disorder? J Clin Psychiatry 1990;51 Suppl: 36-43; discussion 55-8. 66. Agid O, Lerer B. Risperidone augmentation of paroxe- tine in a case of severe, treatment-refractory obsessive- compulsive disorder without comorbid psychopatho- logy. J Clin Psychiatry 1999;60:55-6. 67. Baker RW, Chengappa KN, Baird JW, Steingard S, Christ MA, Schooler NR. Emergence of obsessive com- pulsive symptoms during treatment with clozapine. J Clin Psychiatry 1992;53:439-42. 68. Vandenbergh DJ, Persico AM, Hawkins AL, Griffin CA, Li X, Jabs EW, et al. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 1992;14:1104-6. 69. Miller GM, Madras BK. Polymorphisms in the 3'- Yonsei Med J Vol. 47, No. 4, 2006